<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Nasrallah, Henry A</style></author><author><style face="normal" font="default" size="100%">Kramer, Michelle</style></author><author><style face="normal" font="default" size="100%">Hough, David</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Paliperidone Palmitate for the Treatment of Schizophrenia—Selected Posters</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><abstract><style  face="normal" font="default" size="100%">Adherence to the use of oral forms of antipsychotic therapy, which usually require daily administration, is a major problem when treating patients with schizophrenia. Poor adherence is common and can lead to recurrence of symptoms and hospitalization. Paliperidone palmitate is a long-acting injectable formulation that may simplify the medication regimen for both patients and caregivers. This article discusses 3 double-blind, placebo-controlled randomized studies in patients with schizophrenia reported the efficacy and safety of 25, 50, or 100 mg equivalent paliperidone palmitate injected IM every 4 weeks.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>